Low CSF Levels of Both α-Synuclein and the α-Synuclein Cleaving Enzyme Neurosin in Patients with Synucleinopathy

• Published in: PloS one Vol. 8; no. 1; p. e53250
• Main Authors: Wennström, Malin, Surova, Yulia, Hall, Sara, Nilsson, Christer, Minthon, Lennart, Boström, Fredrik, Hansson, Oskar, Nielsen, Henrietta M.
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 2013; Public Library of Science (PLoS)
• Subjects: Aged; Aged, 80 and over; alpha-Synuclein - cerebrospinal fluid; Alzheimer Disease - cerebrospinal fluid; Alzheimer's disease; Alzheimers disease; Amino acids; Apolipoproteins; Bioindicators; Biology; Biomarkers; Biomarkers - cerebrospinal fluid; Brain research; Cerebrospinal fluid; Clinical Medicine; Dementia; Dementia disorders; Enzyme-linked immunosorbent assay; Enzymes; Female; Fluids; Humans; In vivo methods and tests; Kallikreins - cerebrospinal fluid; Kinases; Klinisk medicin; Laboratories; Lewy bodies; Lewy Body Disease - cerebrospinal fluid; Male; Medical and Health Sciences; Medical diagnosis; Medicin och hälsovetenskap; Medicine; Memory; Middle Aged; Movement disorders; Neurodegenerative diseases; Neurologi; Neurology; Parkinson Disease - cerebrospinal fluid; Parkinson's disease; Patients; Phosphorylation; Proteins; Studies; Substrates; Synuclein; Tau protein; Sweden
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0053250

Neurosin is a protease that in vitro degrades α-synuclein, the main constituent of Lewy bodies found in brains of patients with synucleinopathy including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Several studies have reported reduced cerebrospinal fluid (CSF) levels of α-synuclein in synucleinopathy patients and recent data also proposes a significant role of α-synuclein in the pathophysiology of Alzheimer's disease (AD). To investigate potential links between neurosin and its substrate α-synuclein in vivo we used a commercially available sandwich ELISA and an in-house developed direct ELISA to quantify CSF levels of α-synuclein and neurosin in patients diagnosed with DLB, PD and PD dementia (PDD) versus AD patients and non-demented controls. We found that patients with synucleinopathy displayed lower CSF levels of neurosin and α-synuclein compared to controls and AD patients. In contrast, AD patients demonstrated significantly increased CSF α-synuclein but similar neurosin levels compared to non-demented controls. Further, CSF neurosin and α-synuclein concentrations were positively associated in controls, PD and PDD patients and both proteins were highly correlated to CSF levels of phosphorylated tau in all investigated groups. We observed no effect of gender or presence of the apolipoprotein Eε4 allele on neither neurosin or α-synuclein CSF levels. In concordance with the current literature our study demonstrates decreased CSF levels of α-synuclein in synucleinopathy patients versus AD patients and controls. Importantly, decreased α-synuclein levels in patients with synucleinopathy appear linked to low levels of the α-synuclein cleaving enzyme neurosin. In contrast, elevated levels of α-synuclein in AD patients were not related to any altered CSF neurosin levels. Thus, altered CSF levels of α-synuclein and neurosin in patients with synucleinopathy versus AD may not only mirror disease-specific neuropathological mechanisms but may also serve as fit candidates for future biomarker studies aiming at identifying specific markers of synucleinopathy.